Active Biotech to present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference


Active Biotech (Stockholm: ACTI.ST) will be presenting the company at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference being held May 4-5 at the InterContinental Hotel in Paris, France.
The presentation, scheduled to take place on Wednesday May 4 at 08:00-08:20 am (local time) will include the development of Active Biotech's oral MS drug (laquinimod) that is ongoing in partnership with Teva Pharmaceutical Industries, a novel concept for the treatment of lung cancer (ANYARA) as well as an update of the other clinical projects. A live and archived web cast will be available at and at
For more details about Active Biotech and ongoing projects, visit our web page
Lund, 29 April, 2005
Active Biotech AB (publ)
Sven Andréasson
President & CEO
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA.

Active Biotech AB
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50